Chao TF, et al. - From the Taiwan National Health Insurance Research Database, from 2012 to 2015, individuals with atrial fibrillation (AF, n = 64,169) aged ≥ 65 years who received at least one non-vitamin K antagonist oral anticoagulants (NOACs) (dabigatran, rivaroxaban, or apixaban) or warfarin prescription were recognized in order to evaluate the clinical outcomes of NOACs in comparison with warfarin for stroke prevention in old people with AF. In comparison with warfarin, NOACs were related to a significantly lower risk of adverse events, with heterogeneity in treatment influences among various age levels. In all, the obvious safety sign in favor of NOACs over warfarin was apparent despite the age strata, being most significant in the eldest.